Business Description
Acrivon Therapeutics Inc
NAICS : 541713
SIC : 2833
ISIN : US0048901096
Description
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 24.74 | |||||
Equity-to-Asset | 0.9 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.06 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -130.9 | |||||
3-Year EPS without NRI Growth Rate | -88.1 | |||||
3-Year FCF Growth Rate | -108.7 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 22.66 | |||||
9-Day RSI | 24.68 | |||||
14-Day RSI | 30.72 | |||||
6-1 Month Momentum % | 56.91 | |||||
12-1 Month Momentum % | -40.43 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 12.4 | |||||
Quick Ratio | 12.4 | |||||
Cash Ratio | 12.16 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -20.5 | |||||
Shareholder Yield % | 0.29 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -47.36 | |||||
ROA % | -43.32 | |||||
ROIC % | -378.82 | |||||
ROC (Joel Greenblatt) % | -1015.85 | |||||
ROCE % | -50.57 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.27 | |||||
Price-to-Tangible-Book | 1.27 | |||||
EV-to-EBIT | -1.07 | |||||
EV-to-Forward-EBIT | -0.93 | |||||
EV-to-EBITDA | -1.08 | |||||
EV-to-FCF | -1.49 | |||||
Price-to-Net-Current-Asset-Value | 1.38 | |||||
Price-to-Net-Cash | 1.41 | |||||
Earnings Yield (Greenblatt) % | -93.46 | |||||
FCF Yield % | -26.87 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ACRV
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Acrivon Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -2.89 | ||
Beta | 0 | ||
Volatility % | 98.45 | ||
14-Day RSI | 30.72 | ||
14-Day ATR ($) | 0.461875 | ||
20-Day SMA ($) | 6.8325 | ||
12-1 Month Momentum % | -40.43 | ||
52-Week Range ($) | 3.19 - 13.5 | ||
Shares Outstanding (Mil) | 30.88 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Acrivon Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Acrivon Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Acrivon Therapeutics Inc Frequently Asked Questions
What is Acrivon Therapeutics Inc(ACRV)'s stock price today?
The current price of ACRV is $6.08. The 52 week high of ACRV is $13.50 and 52 week low is $3.19.
When is next earnings date of Acrivon Therapeutics Inc(ACRV)?
The next earnings date of Acrivon Therapeutics Inc(ACRV) is 2024-08-09 Est..
Does Acrivon Therapeutics Inc(ACRV) pay dividends? If so, how much?
Acrivon Therapeutics Inc(ACRV) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |